

(a) Recommendation for determining the appropriate evidence strength level for PM3 and BS2

Supporting	Moderate	Strong
1 point	2 points	4 or more points

(b) Points per FANCN Proband (PM3)

	Points per Proband	
Classification/ Zygosity of other variant	P or LP in trans or homozygote	Phase unknown
Phenotype consistent	2	1

(c) Points per Unaffected Adult Proband (BS2)

	Points per Unaffected Adult Proband		
Classification/ Zygosity of other variant	Confirmed in trans with P or LP in same gene	Homozygote	Phase unknown
Patient first cancer onset >50 years or cancer-unaffected at age at last follow up of >50 years	4	2	1
Patient first cancer onset 40-50 years or unaffected at age of last follow up of 40-50 years	2	1	0.5